Evaluation of a novel calpain inhibitor as a treatment for cataract

Clinical and Experimental Ophthalmology

Volumn 36, Issue 9, 2008, Pages 852-860

  Lee, Hannah Y Y ^a   Morton, James D ^a   Robertson, Lucinda J G ^a   McDermott, Joshua D ^a   Bickerstaffe, Roy ^a   Abell, Andrew D ^b,c   Jones, Matthew A ^b   Mehrtens, Janna M ^b   Coxon, James M ^b  

^a LINCOLN UNIVERSITY   (New Zealand)

^b UNIVERSITY OF CANTERBURY   (New Zealand)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Calpain inhibitor; CAT0059; Cytoskeleton; Inherited cataract

Indexed keywords

CALPAIN 2; CALPASTATIN; CAT 0059; CYSTEINE PROTEINASE; CYTOSKELETON PROTEIN; EYE DROPS; EYE PROTEIN; PROTEINASE INHIBITOR; SJA 6017; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONTROLLED STUDY; DISEASE COURSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; OINTMENT; OUTCOME ASSESSMENT; PROTEIN DEGRADATION; SLIT LAMP; TREATMENT DURATION;

ANIMALS; CALPAIN; CATARACT; CELL SURVIVAL; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; DIPEPTIDES; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HUMANS; MODELS, MOLECULAR; OINTMENTS; OPHTHALMIC SOLUTIONS; PYRROLES; SHEEP; SHEEP DISEASES;

EID: 62149139337     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2009.01925.x     Document Type: Article

References (49)

1. Carragher NO. Calpain inhibition: A therapeutic strategy targeting multiple disease states. Curr Pharm Des 2006; 12: 615-38.
2. Brian G, Taylor H. Cataract blindness-challenages for the 21st century. Bull World Health Organ 2001; 79: 249-56.
3. Zatz M, Starling A. Calpains and disease. N Engl J Med 2005; 352: 2413-23.
4. Murachi T. Calpain and calpastatin. Trends Biochem Sci 1983; 8: 167-9.
5. Cuerrier D, Moldoveanu T, Campbell RL et al. Development of calpain-specific inactivators by screening of positional-scanning epoxide libraries. J Biol Chem 2007; 282: 9600-11.
6. Wang KKW, Yuen P. Calpain inhibition: An overview of its therapeutic potential. Trends Pharmacol Sci 1994; 15: 412-19.
7. Yamamoto S, Shimizu K, Shimizu K, Suzuki K, Nakagawa Y, Yamamoto T. Calcium-dependent cysteine proteinase (calpain) in human arthritic synovial joints. Arthritis Rheum 1992; 35: 1309-17.
8. Bhattacharyya J, Thomas K, Sayeed NM. Calcium-dependent and calcium-independent proteases activities in skeletal muscle during sepsis. Circ Shock 1991; 35: 117-22.
9. Saido K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium dependant neural protease (calpain) in the brain in Alzheimer's disease: a potential molecular basis for neuronal degradation. Proc Natl Acad Sci USA 1993; 90: 2628-32.
10. Azuma M, David LL, Shearer TR. Cysteine protease inhibitor E64 reduces rate of formation of selenite cataract in the whole animal. Curr Eye Res 1991; 10: 657-66.
11. Azuma M, David LL, Shearer TR. Superior prevention of calcium ionophore cataract by E64d. Biochim Biophys Acta 1992; 1180: 215-20.
12. Fukiage C, Azuma M, Nakamura Y, Tamada Y, Nakamura M, Shearer TR. SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: amelioration of cataract in cultured rat lenses. Biochim Biophys Acta 1997; 1361: 304-12.
13. Kadoya K, Azuma M, David LL, Shearer TR. Role of calpain in hydrogen peroxide induced cataract. Curr Eye Res 1993; 12: 341-6.
14. Sanderson J, Marcantonio JM, Duncan G. Calcium ionophore induced proteolysis and cataract: Inhibition by cell permeable calpain antagonists. Biochem Biophys Res Commun 1996; 218: 893-901.
15. Tsujinaka T, Kajiwara Y, Kambayashi J et al. Synthesis of a new cell penetrating calpain inhibitor (calpeptin). Biochem Biophys Res Commun 1988; 153: 1201-8.
16. Inoue J, Nakamura M, Cui Y et al. Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor. J Med Chem 2003; 46: 868-71.
17. Robertson LJG, Morton JD, Yamaguchi M, Bickerstaffe R, Shearer TR, Azuma M. Calpain may contribute to hereditary cataract formation in sheep. Invest Ophthalmol Vis Sci 2005; 46: 4634-40.
18. Brooks HV, Jolly RD, West DM, Bruere AN. An Inherited Cataract in New Zealand Romney Sheep. N Z Vet J 1982; 30: 113-14.
19. Brooks HV, Jolly RD, Paterson CA. The pathology of an inherited cataract of sheep. Current Eye Research 1983; 2: 625-32.
20. 2+ -overload in ovine lens culture. Vet Ophthalmol 2008; 11: 347-55.
21. Jones M, Abell A, Morton J et al. Synthesis, biological evaluation and molecular modeling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors. Bioorg Med Chem 2008; 16: 6911-23.
22. Thompson VF, Saldaña S, Cong J, Goll DEA. BODIPY fluorescent microplate assay for measuring activity of calpains and other proteases. Anal Biochem 2000; 279: 170-8.
23. Davies PD, Duncan G, Pynsent PB, Arber DL, Lucas VA. Aqueous humour glucose concentration in cataract patients and its effect on the lens. Exp Eye Res 1984; 39: 605-9.
24. Piercy DWT. Factors influencing the penetration of therapeutic substances into the eye following topical application. Vet Rec 1985; 14: 99-104.
25. Vrensen GFJ, Sanderson J, Willekens B, Duncan G. Calcium localization and ultrastructure of clear and pCMPS-treated rat lenses. Invest Ophthalmol Vis Sci 1995; 36: 2287-95.
26. 2+-induced protein loss, vimentin cleavage and opacification. Invest Ophthalmol Vis Sci 2000; 41: 2255-61.
27. Shoeman RL, Traub P. Calpains and the cytoskeleton. In: Mellgren RL, Murachi T, eds. Intracellular Calcium-Dependent Proteolysis. Boca Raton, FL: CRC Press, 1990; 191-209.
28. Truscott RJW, Marcantonio JM, Tomlinson J, Duncan G. Calcium-induced opacification and proteolysis in the intact rat lens. Invest Ophthalmol Vis Sci 1990; 31: 2405-11.
29. Marcantonio JM, Sanderson J. Calcium-induced cytoskeletal proteolysis and lens opacification. Nova Acta Leopold 1997; 75: 145-452.
30. Lee VHL, Robinson JR. Topical ocular drug delivery: Recent developments and future challenages. J Ocul Pharmacol 1986; 2: 76-108.
31. Bassnett S. Lens Organelle degradation. Exp Eye Res 2002; 74: 1-6.
32. David L, Shearer T, Shih M. Sequence analysis of lens beta-crystallins suggests involvement of calpain in cataract formation. J Biol Chem 1993; 268: 1937-40.
33. Robertson LJG, David LL, Riviere MA, Wilmarth PA, Muir MS, Morton JD. Susceptibility of ovine lens crystallins to proteolytic cleavage during formation of hereditary cataract. Invest Ophthalmol Vis Sci 2008; 49: 1016-22.
34. Goll D, Thompson VF, Li H, Wei W, Cong J. The Calpain System. Physiol Rev 2003; 83: 731-801.
35. Marcantonio JM. Calcium-induced disruption of the lens cytoskeleton. Ophthalmic Res 1996; 28: 48-50.
36. Marcantonio JM, Duncan G. Calcium-induced degradation of the lens cytoskeleton. Biochem Soc Trans 1991; 19: 1148-50.
37. Nakamura M, Yamaguchi M, Sakai O, Inoue J. Exploration of cornea permeable calpain inhibitors as anticataract agents. Bioorg Med Chem 2003; 11: 1371-9.
38. Pavao A, Lee D, Ethier C, Johnson M, Anderson P, Epstein D. Two-dimensional gel electrophoresis of calf aqueous humor, serum, and filter-bound proteins. Invest Ophthalmol Vis Sci 1989; 30: 731-8.
39. Tripathi RC, Millard CB, Tripathi BJ. Protein composition of human aqueous humor: SDS-PAGE analysis of surgical and post-mortem samples. Exp Eye Res 1989; 48: 117-30.
40. Burstein NL. Review: Corneal penetration and ocular bioavailability of drugs. J Ocul Pharmacol 1985; 1: 309-26.
41. Urtti A, Salminen L. Animal pharmacolinetic studies. In: Mitra AK, ed. Opthalmic Drug Delivery Systems. New York: Marcel Dekker, 1993; 121-36.
42. McLaren JW, Ziai N, Brubaker R. A simple three-compartment model of anterior segment kinetics. Exp Eye Res 1993; 56: 355-66.
43. Friedrich SW, Cheng YL, Saville BA. Theoretical corneal permeation model for ionizable drugs. J Ocul Pharmacol 1993; 9: 229-49.
44. Davis NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol P 2000; 27: 558-62.
45. van De Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem 2001; 44: 1313.
46. Tan AG, Wang JJ, Rochtchina E, Mitchell P. Comparison of age-specific cataract prevalence in two population-based surveys 6years apart. Biomed Cent Ophthalmol 2006; 6: 17. Doi: 10.1186/1471-2415-6-17.
47. Livingston P, Guest C, Stanislavsky Y et al. A population-based estimate of cataract prevalence: The Melbourne Visual Impairment Project experience. Dev Ophthalmol 1994; 26: 1-6.
48. Duncan G, Bushell AR. Ion analyses of human cataractous lenses. Exp Eye Res 1975; 20: 223-30.
49. Leinonen J, Laatikainen L. The decrease of visual acuity in cataract patients waiting for surgery. Acta Ophthalmol Scand 1999; 77: 681-4.